- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Minot Light Capital's Largest Performance Detractor in Q4: Journey Medical (DERM) | 2 | Insider Monkey | ||
| 16.12.24 | Journey Medical Co. (NASDAQ:DERM) Sees Large Increase in Short Interest | 3 | MarketBeat | ||
| 13.11.24 | Journey Medical GAAP EPS of -$0.12 beats by $0.03, revenue of $14.63M beats by $0.24M | 1 | Seeking Alpha | ||
| 12.11.24 | Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | 119 | GlobeNewswire (Europe) | U.S. FDA approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025... ► Artikel lesen | |
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11.24 | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.24 | FDA approves Journey Medical's Emrosi to treat inflammatory lesions of rosacea | - | PMLiVE | ||
| 05.11.24 | FDA approves Journey Medical's rosacea treatment Emrosi | 1 | Pharmaceutical Technology | ||
| 04.11.24 | Journey Medical, with FDA nod, won't stop believing it can establish new rosacea standard of care | 3 | FiercePharma | ||
| 04.11.24 | What's Going On With Journey Medical Stock Today? | 2 | Benzinga.com | ||
| 04.11.24 | Journey Medical: FDA Approves Emrosi For Treatment Of Inflammatory Lesions Of Rosacea | 1 | RTTNews | ||
| 04.11.24 | Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea | 136 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and... ► Artikel lesen | |
| 04.11.24 | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 03.10.24 | Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 2 | GlobeNewswire (USA) | ||
| 01.10.24 | PVG Asset Management Corp Purchases New Holdings in Journey Medical Co. (NASDAQ:DERM) | 2 | MarketBeat | ||
| 09.09.24 | Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference | 1 | GlobeNewswire (USA) | ||
| 06.09.24 | Lake Street starts Journey Medical with Buy, sets stock target on product launch | 1 | Investing.com | ||
| 04.09.24 | Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 2 | GlobeNewswire (USA) | ||
| 13.08.24 | Journey Medical Corporation (NASDAQ:DERM) Q2 2024 Earnings Call Transcript | 2 | Insider Monkey | ||
| 13.08.24 | Journey Medical holds steady with Buy rating on revenue beat | 2 | Investing.com | ||
| 13.08.24 | Earnings call: Journey Medical on track with solid Q2 results, DFD-29 launch | 2 | Investing.com |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 25,715 | +0,31 % | Dividendenbekanntmachungen (24.01.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACERINOX SA ES0132105018 - EUR ALBERTSONS COMPANIES INC US0130911037 0,15 USD 0,144 EUR AUTO TRADER GROUP PLC GB00BVYVFW23 0,035... ► Artikel lesen | |
| GILEAD SCIENCES | 89,96 | -1,04 % | Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years | ||
| VERTEX PHARMACEUTICALS | 422,00 | -0,28 % | Vertex Pharmaceuticals Incorporated: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10 | Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 7,980 | +4,29 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 7,500 | -0,53 % | Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported... ► Artikel lesen | |
| ROCKET LAB USA | 27,800 | -1,07 % | Raumfahrt: Im SpaceRace 2.0 geben die USA unter Präsident Trump mächtig Gas | ||
| OPKO HEALTH | 1,464 | +4,12 % | OPKO Health, Inc.: ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program | Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 110,00 | +3,77 % | ROUNDUP: Ligand Pharmaceuticals Boosts FY24 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) raised its core adjusted earnings and... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 119,05 | +0,29 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference | DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare... ► Artikel lesen | |
| ROYALTY PHARMA | 30,530 | +0,96 % | Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now? | ||
| TG THERAPEUTICS | 31,925 | +4,91 % | Here's Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX) | ||
| CATALYST PHARMACEUTICALS | 22,100 | +2,08 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE in Japan | CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 9,500 | +2,15 % | CRBP-Aktie erreicht 52-Wochen-Tief bei 10,43 US-Dollar | ||
| CATALENT | 59,93 | 0,00 % | Galapagos inks agreement with Catalent for experimental CAR-T therapy | ||
| TALPHERA | 0,675 | +6,97 % | Talphera, Inc.: Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study | Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week
The FDA agreed to... ► Artikel lesen |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,030 (-0,74 %) liegt der Kurs bei 4,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.
